ALDARA: Uses, Dosage & Side Effects

What Is ALDARA and What Is It Used For?

ALDARA contains the active substance imiquimod, a synthetic compound belonging to the imidazoquinoline family. It was the first drug in its class to be approved for clinical use and represents a fundamentally different approach to treating certain skin conditions. Unlike conventional treatments that directly destroy abnormal tissue through surgery, cryotherapy, or cytotoxic agents, imiquimod works by harnessing the patient’s own immune system to recognize and eliminate the targeted pathology.

The mechanism of action centers on Toll-like receptor 7 (TLR7), a pattern recognition receptor found on innate immune cells such as monocytes, macrophages, and plasmacytoid dendritic cells in the skin. When imiquimod binds to TLR7, it triggers a cascade of immune signaling that leads to the production of multiple pro-inflammatory cytokines. Key among these are interferon-alpha (IFN-α), tumor necrosis factor-alpha (TNF-α), and various interleukins (IL-1, IL-6, IL-8, IL-12). These cytokines have both direct antiviral and antitumor properties and also activate adaptive immune responses, including the stimulation of natural killer (NK) cells and cytotoxic T lymphocytes that specifically target virus-infected or malignant cells.

Following topical application, systemic absorption of imiquimod through intact skin is minimal—less than 0.9% of an applied dose reaches the bloodstream. This means the drug acts predominantly at the local application site, which accounts for the characteristic local skin reactions seen during treatment while minimizing systemic side effects. The local immune activation leads to an inflammatory response that can manifest as redness, swelling, erosion, and crusting—signs that the medication is stimulating the desired immune response.

ALDARA cream is approved by regulatory authorities worldwide, including the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA), for three distinct indications:

External Genital and Perianal Warts (Condylomata Acuminata)

Genital warts are caused by human papillomavirus (HPV), most commonly HPV types 6 and 11. They appear as flesh-colored, soft growths on the external genitalia and around the anal opening. HPV is one of the most common sexually transmitted infections worldwide, and while most HPV infections clear spontaneously, persistent infections can lead to visible warts that may cause significant psychological distress and physical discomfort. ALDARA stimulates the local immune response against HPV-infected cells, helping the body clear the virus and eliminate the warts. Clinical trials have demonstrated complete clearance rates of approximately 50% in women and 33% in men treated for up to 16 weeks.

Superficial Basal Cell Carcinoma (sBCC)

Basal cell carcinoma is the most common form of skin cancer globally, affecting millions of people each year. Superficial BCC is a subtype that grows slowly and remains confined to the upper layers of the skin (epidermis and papillary dermis). It typically appears as a flat, reddish, slightly scaly patch, most often in sun-exposed areas. While sBCC has an extremely low risk of metastasis, untreated lesions can grow and cause significant local tissue destruction, particularly on the face. ALDARA provides a non-surgical treatment option that activates antitumor immunity at the application site. The immune response triggered by imiquimod helps destroy the malignant basal cells. Studies have shown histological clearance rates of approximately 80–85% with the recommended 6-week treatment course applied 5 days per week.

Actinic Keratosis (AK)

Actinic keratoses are rough, scaly patches that develop on areas of skin that have been chronically exposed to ultraviolet (UV) radiation from sunlight. They are considered precancerous lesions because a small percentage (estimated at 5–10% over 10 years) may progress to squamous cell carcinoma if left untreated. AK lesions are most commonly found on the face, scalp, ears, and backs of the hands in fair-skinned individuals with a history of significant sun exposure. ALDARA is specifically indicated for the treatment of clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on the face and scalp in immunocompetent adults. The immune response induced by imiquimod eliminates the dysplastic keratinocytes that comprise AK lesions.

What Should You Know Before Using ALDARA?

Contraindications

ALDARA cream must not be used if you have a known allergy (hypersensitivity) to imiquimod or to any of the other ingredients in the formulation, including isostearic acid, benzyl alcohol, cetyl alcohol, stearyl alcohol, white soft paraffin, polysorbate 60, sorbitan stearate, glycerol, methyl parahydroxybenzoate (E218), propyl parahydroxybenzoate (E216), xanthan gum, or purified water. Allergic reactions may manifest as a rash, itching, swelling, or difficulty breathing and require immediate medical attention.

The cream is for external use only and must not be applied to internal mucosal surfaces. This includes the inside of the urethra, vagina, cervix, or rectum. For genital warts, only external warts on the outer genital skin and perianal area should be treated. Internal genital or anal warts require different treatment approaches that your healthcare provider can discuss with you.

Warnings and Precautions

Before starting ALDARA treatment, inform your doctor if you have any of the following conditions or circumstances, as they may affect the safety and efficacy of treatment:

• Previous use of imiquimod or similar medications: If you have used ALDARA or other imidazoquinoline-based products before, let your doctor know, as this may influence the treatment plan.
• Autoimmune conditions: Patients with autoimmune diseases (such as lupus, rheumatoid arthritis, or psoriasis) may experience worsening of their condition during ALDARA treatment, because the drug stimulates immune activity.
• Organ transplant recipients: If you have received an organ transplant and are taking immunosuppressive medications, ALDARA may be less effective or may interact with your immunosuppressive regimen. Close medical supervision is essential.
• Immunocompromised patients: Individuals with weakened immune systems (due to disease or medications) should not use ALDARA for more than one treatment course. If you are HIV-positive, ALDARA has been shown to be less effective, and you should discuss alternative treatments with your doctor.
• Abnormal blood counts: If you have known abnormalities in your blood cell counts, inform your doctor. Imiquimod’s immune-stimulating effects may, in rare cases, affect blood cell production.
• Open wounds or unhealed skin: Do not begin ALDARA treatment until the treatment area has fully healed from any previous procedures (surgery, cryotherapy, laser treatment) or other skin conditions.

Special Precautions for Genital Warts

Men with warts located under the foreskin must retract the foreskin daily and wash the area thoroughly. Failure to maintain proper hygiene in this area during treatment increases the risk of foreskin tightening (phimosis), swelling, and skin breakdown, which can make it difficult or impossible to retract the foreskin. If these symptoms develop, treatment should be discontinued immediately and medical advice sought.

ALDARA cream can weaken condoms and diaphragms made of latex or polyisoprene. Therefore, the cream should be applied after—not before—sexual intercourse. It is important to understand that ALDARA treats visible warts but does not prevent the transmission of HPV or other sexually transmitted infections (STIs) to sexual partners. Safe sex practices should be maintained throughout and after treatment.

Special Precautions for Basal Cell Carcinoma and Actinic Keratosis

Patients using ALDARA for superficial BCC or actinic keratosis should avoid sun exposure, sunlamps, and tanning beds during treatment. The treated skin is more sensitive to UV radiation, and sun exposure may exacerbate local skin reactions. Wear protective clothing and a wide-brimmed hat when outdoors. During treatment, the skin in the application area will likely appear noticeably different from the surrounding normal skin—this is expected and will improve after treatment ends.

Pregnancy and Breastfeeding

If you are pregnant, planning to become pregnant, or breastfeeding, consult your doctor before using ALDARA. Animal reproductive studies have not demonstrated direct or indirect harmful effects on pregnancy or fetal development. However, there are no adequate, well-controlled studies in pregnant women. Your doctor will weigh the potential benefits against the potential risks before prescribing ALDARA during pregnancy.

It is not known whether imiquimod or its metabolites are excreted in human breast milk. As a precautionary measure, breastfeeding is not recommended during treatment with ALDARA. Discuss the timing of treatment with your healthcare provider if you are nursing or plan to nurse.

Driving and Operating Machinery

ALDARA cream has no known effect on the ability to drive or operate machinery. The medication is applied topically and has minimal systemic absorption, so it does not cause drowsiness, dizziness, or cognitive impairment that would affect these activities.

Important Information About Excipients

ALDARA cream contains several inactive ingredients that may cause reactions in sensitive individuals. Methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216) may cause allergic reactions, which may be delayed. Cetyl alcohol and stearyl alcohol can cause local skin reactions such as contact dermatitis. Each single-use sachet contains 5 mg of benzyl alcohol, which may cause allergic reactions and mild local irritation.

How Does ALDARA Interact with Other Drugs?

One of the advantages of ALDARA as a topical medication is its minimal systemic absorption. Less than 0.9% of a topically applied dose of imiquimod reaches the bloodstream, which means that the potential for interactions with systemically administered medications is very low. No clinical studies have identified specific drug-drug interactions with ALDARA cream, and no medications are formally listed as contraindicated for concurrent use.

However, there are important theoretical considerations and practical precautions that patients and healthcare providers should be aware of:

For patients taking immunosuppressive medications following organ transplantation, the reduced immune function may significantly decrease ALDARA’s effectiveness. In such cases, physicians typically recommend alternative treatment approaches such as surgical excision, cryotherapy, or photodynamic therapy for the conditions ALDARA is used to treat.

Always inform your healthcare provider about all medications you are currently taking, including prescription drugs, over-the-counter products, herbal supplements, and other topical treatments. While significant interactions are unlikely with ALDARA, a complete medication history helps your doctor provide the safest and most effective care.

What Is the Correct Dosage of ALDARA?

ALDARA cream should always be used exactly as prescribed by your doctor. The dosing schedule, application technique, and treatment duration differ depending on which condition is being treated. Each single-use sachet contains 250 mg of cream and should be opened fresh for each application. Discard any unused cream after application—do not save opened sachets for later use.

General Application Instructions

Regardless of the condition being treated, the following steps should be followed for every application:

1. Wash hands thoroughly before and after applying the cream.
2. Clean the treatment area with mild soap and water, then dry thoroughly before application.
3. Open a new sachet and squeeze a small amount of cream onto your fingertip.
4. Apply a thin layer of cream to the treatment area and gently rub it in until absorbed.
5. Discard the opened sachet and wash your hands with soap and water.
6. Leave the cream on for the specified duration (see condition-specific instructions below).
7. Wash off the cream with mild soap and water after the recommended contact time.

Do not cover the treated area with bandages, dressings, or occlusive wrappings. Do not bathe or shower while the cream is on the skin.

Genital Warts (Condylomata Acuminata)

Apply a thin layer of ALDARA cream to the clean, dry wart area at bedtime and gently massage the cream in until it is absorbed into the skin. The cream should remain on the warts for 6 to 10 hours overnight. In the morning, wash the treated area with mild soap and water to remove the cream.

Superficial Basal Cell Carcinoma (sBCC)

Apply ALDARA cream to the affected area and 1 cm of skin surrounding the lesion at bedtime, 5 days per week for 6 consecutive weeks. The cream should remain on the skin for approximately 8 hours overnight. In the morning, wash the treated area with mild soap and water. Your doctor will assess the treatment site approximately 12 weeks after the end of the 6-week treatment course to determine clinical response.

Actinic Keratosis (AK)

Apply ALDARA cream to the affected area at bedtime, 3 times per week for 4 weeks. After the initial 4-week course, your doctor will evaluate your skin approximately 4 weeks later. If not all lesions have cleared, a second 4-week treatment course may be prescribed following the same dosing schedule. The cream should remain on the skin for approximately 8 hours, then be washed off with mild soap and water.

Children and Adolescents

ALDARA cream is not recommended for use in children and adolescents under 18 years of age. There is insufficient data on the safety and efficacy of imiquimod in this population. If a child or adolescent has a condition that might otherwise be treated with ALDARA, a pediatric dermatologist should be consulted for appropriate alternative treatments.

Missed Dose

If you forget to apply ALDARA cream at the scheduled time, apply it as soon as you remember and then continue with your regular dosing schedule. Do not apply the cream more than once per day to compensate for a missed dose. Maintaining the regular schedule as closely as possible helps ensure optimal treatment outcomes.

Overdose

If too much cream is applied to the skin, wash off the excess with mild soap and water. Once any skin reaction subsides, you may resume treatment as directed. Persistent overdose of topical imiquimod increases the risk and severity of local skin reactions. If ALDARA cream is accidentally swallowed, seek immediate medical attention at your nearest emergency department.

What Are the Side Effects of ALDARA?

Like all medicines, ALDARA can cause side effects, although not everyone experiences them. Many of the side effects seen with ALDARA are a direct consequence of its immune-stimulating mechanism of action and occur at or near the application site. Local skin reactions are actually considered a positive sign that the medication is working as intended—the inflammation represents the body’s immune response being activated against the targeted pathology.

However, if skin reactions become excessively severe or uncomfortable, do not apply more cream. Instead, wash the area with mild soap and water and contact your healthcare provider. Your doctor may recommend a temporary break (“rest period”) from treatment before resuming. Some patients have experienced changes in skin color at the treatment site; while these changes usually resolve over time, they may become permanent in some individuals.

Side Effects for Genital Warts Treatment

Side Effects for Superficial BCC Treatment

Side Effects for Actinic Keratosis Treatment

Additional Safety Information

In some patients, decreases in blood cell counts (red blood cells, white blood cells, or platelets) have been observed. A reduction in blood cells may make you more susceptible to infections, cause you to bruise more easily, or lead to unusual fatigue. If you experience any of these symptoms, inform your doctor promptly.

Patients with pre-existing autoimmune conditions may experience a worsening of their disease during ALDARA treatment. This is a consequence of the drug’s immune-stimulating properties. Report any changes in your autoimmune condition to your doctor during treatment.

A small number of patients have experienced some hair loss at or near the treatment site. Rare cases of severe skin reactions have been reported, including erythema multiforme-like reactions with target-shaped skin lesions, potentially accompanied by itching, fever, malaise, joint pain, vision changes, or burning/sore eyes and mouth sores. If you develop any of these symptoms, stop using ALDARA immediately and seek medical attention.

How Should You Store ALDARA?

Proper storage of ALDARA cream is essential to maintain its effectiveness and safety throughout the treatment course. The following storage guidelines should be observed:

• Temperature: Store at or below 25°C (77°F). Do not freeze the cream. Avoid storing in areas exposed to excessive heat, such as near radiators, in direct sunlight, or in vehicles during hot weather.
• Keep out of reach of children: Store ALDARA in a location inaccessible to children. The cream is a potent medication that can cause harm if misused or accidentally ingested.
• Check expiration dates: Do not use ALDARA after the expiration date (EXP) printed on the outer carton and individual sachet labels. Expired medication may not provide the intended therapeutic effect and could potentially cause harm.
• Single-use sachets: Each sachet is designed for a single application. Once opened, any leftover cream should be discarded. Do not save opened sachets for future use, as the cream is not preserved for extended storage after opening.
• Disposal: Do not dispose of ALDARA cream by flushing it down the toilet or pouring it into drains. Return unused or expired medication to a pharmacy for proper disposal. This helps protect the environment.

ALDARA cream is a white to slightly yellow cream supplied in polyester/aluminum foil sachets. Each sachet contains 250 mg of cream. Packages are available in 12- or 24-sachet configurations, though not all pack sizes may be marketed in all countries.

What Does ALDARA Contain?

Understanding the full composition of ALDARA cream is important, particularly for patients with known allergies or sensitivities to specific pharmaceutical ingredients. The formulation has been designed to provide stable delivery of imiquimod to the skin while maintaining an acceptable texture and shelf life.

Active Ingredient

The active substance in ALDARA cream is imiquimod. Each single-use sachet contains 250 mg of cream at a concentration of 5% (50 mg of imiquimod per gram of cream), providing a total of 12.5 mg of imiquimod per sachet. Imiquimod is a synthetic imidazoquinoline compound with the molecular formula C₁₄H₁₆N₄ and a molecular weight of 240.3 g/mol.

Inactive Ingredients (Excipients)

The cream has a white to slightly yellow appearance and a smooth, uniform consistency. Each sachet is sealed in a polyester/aluminum foil laminate to protect the cream from light and moisture degradation. The packaging ensures sterility and consistent drug potency throughout the shelf life of the product.

ALDARA is marketed by Viatris Healthcare Limited (formerly part of Mylan/Meda). The cream is manufactured by Swiss Caps GmbH in Bad Aibling, Germany, under strict pharmaceutical manufacturing standards (Good Manufacturing Practice, GMP).